A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

07 Nov, 2019 ,

The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by cancer will improve the chances of responding to immunotherapy in the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on lung cancers and is known to block the effects of the body's immune system in attacking cancer. Blocking this PD-L1 has been shown to improve the body's immune cells to attack and kill the cancer cells in non-small cell lung cancer. The goal of this study is to see if prior treatment with radiation will allow improved recognition of cancer by the body's immune cells in the presence of MPDL3280A.